NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Insilico Medicine

Insilico Medicine

Private
Hong KongHealthcare & Life Scienceshttps://insilico.com/

Last Round

IPO

Dec 30, 2025

Est. Valuation

$1.72B

Total Funding Raised

$854.01M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Insilico Medicine is a biotechnology company that develops an advanced AI platform and innovative drugs aimed at providing transformative solutions for cancer, fibrosis, immune disorders, central nervous system diseases, and age-related conditions.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Subscription SaaS, Revenue Share

AI Layer

Foundation

Keywords

ai drug discoverygenerative biologysmall molecule designscientific foundation modeltarget discoveryin silico drug designclinical trial predictionbiotech aipharma aidrug discovery platformadmet predictionfrontier ai labai drug pipelinecomputational biologysaas drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Insilico Medicine Comparables

Compare Insilico Medicine with similar companies based on industry and business-model similarity.

Insilico Medicine comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
XtalPi
89%
BenevolentAI
84%
BioMap
83%

Insilico Medicine Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
IPODec 30, 2025
Series EJun 16, 2025
Series EMar 13, 2025
Series EJan 7, 2025
DebtNov 5, 2024
Series D Extension
Aug 11, 2022

Key People

Founding team and executive leadership

Feng Ren

Co-CEO, CSO, Head Of Drug R D

Executive Team

Hong Zhao

EA To CEO

Executive Team

Insilico Medicine Investors

Notable investors and investment history

Insilico Medicine investors
InvestorRounds
Deerfield ManagementSeries C, Series D Extension
AIBasis FundSeries C
Credit Suisse Asset Managementipo
Temasekipo
Baidu VenturesSeries C, Series B
Lake Bleu CapitalSeries C
Winter CapitalSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 30, 2026

    Unified AI framework integrates TargetPro and TargetBench for improved drug development.

  • Mar 24, 2026

    Partnered with ASKA Pharmaceutical Co., Ltd. for drug discovery.

Insilico Medicine Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Insilico Medicine Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Insilico Medicine's valuation, stock price, and market status.

Firmographic Details

HeadquartersHong Kong
Employee Range285
Year Founded2014
Last FundingDec 30, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.